|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MYO19 |
Gene summary for MYO19 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MYO19 | Gene ID | 80179 |
| Gene name | myosin XIX | |
| Gene Alias | MYOHD1 | |
| Cytomap | 17q12 | |
| Gene Type | protein-coding | GO ID | GO:0000266 | UniProtAcc | A0A024R0S9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 80179 | MYO19 | CCI_1 | Human | Cervix | CC | 1.94e-05 | 7.41e-01 | 0.528 |
| 80179 | MYO19 | CCI_3 | Human | Cervix | CC | 8.20e-07 | 6.05e-01 | 0.516 |
| 80179 | MYO19 | sample3 | Human | Cervix | CC | 6.37e-07 | 2.58e-01 | 0.1387 |
| 80179 | MYO19 | T3 | Human | Cervix | CC | 1.10e-06 | 2.36e-01 | 0.1389 |
| 80179 | MYO19 | LZE2T | Human | Esophagus | ESCC | 5.71e-04 | 4.02e-01 | 0.082 |
| 80179 | MYO19 | LZE4T | Human | Esophagus | ESCC | 8.31e-06 | 1.39e-01 | 0.0811 |
| 80179 | MYO19 | LZE7T | Human | Esophagus | ESCC | 6.51e-14 | 5.56e-01 | 0.0667 |
| 80179 | MYO19 | LZE8T | Human | Esophagus | ESCC | 4.28e-04 | 8.05e-02 | 0.067 |
| 80179 | MYO19 | LZE21D1 | Human | Esophagus | HGIN | 1.13e-03 | 2.66e-01 | 0.0632 |
| 80179 | MYO19 | LZE22D1 | Human | Esophagus | HGIN | 4.99e-04 | 1.74e-01 | 0.0595 |
| 80179 | MYO19 | LZE24T | Human | Esophagus | ESCC | 1.90e-13 | 2.60e-01 | 0.0596 |
| 80179 | MYO19 | LZE21T | Human | Esophagus | ESCC | 3.47e-04 | 5.02e-01 | 0.0655 |
| 80179 | MYO19 | LZE6T | Human | Esophagus | ESCC | 1.38e-04 | 2.17e-01 | 0.0845 |
| 80179 | MYO19 | P1T-E | Human | Esophagus | ESCC | 6.70e-09 | 4.92e-01 | 0.0875 |
| 80179 | MYO19 | P2T-E | Human | Esophagus | ESCC | 3.35e-10 | 2.32e-01 | 0.1177 |
| 80179 | MYO19 | P4T-E | Human | Esophagus | ESCC | 2.83e-19 | 4.17e-01 | 0.1323 |
| 80179 | MYO19 | P5T-E | Human | Esophagus | ESCC | 6.46e-19 | 4.71e-01 | 0.1327 |
| 80179 | MYO19 | P8T-E | Human | Esophagus | ESCC | 3.27e-14 | 3.59e-01 | 0.0889 |
| 80179 | MYO19 | P9T-E | Human | Esophagus | ESCC | 1.35e-22 | 4.68e-01 | 0.1131 |
| 80179 | MYO19 | P10T-E | Human | Esophagus | ESCC | 2.23e-26 | 4.72e-01 | 0.116 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003070521 | Liver | HCC | cytoskeleton-dependent intracellular transport | 111/7958 | 195/18723 | 3.25e-05 | 3.28e-04 | 111 |
| GO:000091011 | Liver | HCC | cytokinesis | 100/7958 | 173/18723 | 3.38e-05 | 3.39e-04 | 100 |
| GO:0051646 | Liver | HCC | mitochondrion localization | 34/7958 | 50/18723 | 2.38e-04 | 1.79e-03 | 34 |
| GO:00995182 | Liver | HCC | vesicle cytoskeletal trafficking | 46/7958 | 73/18723 | 3.23e-04 | 2.28e-03 | 46 |
| GO:0000266 | Liver | HCC | mitochondrial fission | 28/7958 | 42/18723 | 1.35e-03 | 7.26e-03 | 28 |
| GO:0051654 | Liver | HCC | establishment of mitochondrion localization | 20/7958 | 29/18723 | 3.61e-03 | 1.60e-02 | 20 |
| GO:0090140 | Liver | HCC | regulation of mitochondrial fission | 21/7958 | 32/18723 | 7.02e-03 | 2.80e-02 | 21 |
| GO:005165610 | Oral cavity | OSCC | establishment of organelle localization | 239/7305 | 390/18723 | 2.46e-19 | 3.31e-17 | 239 |
| GO:00482852 | Oral cavity | OSCC | organelle fission | 265/7305 | 488/18723 | 3.22e-12 | 1.27e-10 | 265 |
| GO:001082117 | Oral cavity | OSCC | regulation of mitochondrion organization | 97/7305 | 144/18723 | 4.78e-12 | 1.83e-10 | 97 |
| GO:00516509 | Oral cavity | OSCC | establishment of vesicle localization | 101/7305 | 161/18723 | 8.79e-10 | 2.17e-08 | 101 |
| GO:000701520 | Oral cavity | OSCC | actin filament organization | 230/7305 | 442/18723 | 1.37e-08 | 2.77e-07 | 230 |
| GO:00516489 | Oral cavity | OSCC | vesicle localization | 105/7305 | 177/18723 | 3.30e-08 | 6.30e-07 | 105 |
| GO:003070510 | Oral cavity | OSCC | cytoskeleton-dependent intracellular transport | 113/7305 | 195/18723 | 6.03e-08 | 1.09e-06 | 113 |
| GO:000091010 | Oral cavity | OSCC | cytokinesis | 97/7305 | 173/18723 | 3.82e-06 | 4.51e-05 | 97 |
| GO:00995184 | Oral cavity | OSCC | vesicle cytoskeletal trafficking | 41/7305 | 73/18723 | 2.18e-03 | 9.95e-03 | 41 |
| GO:00513024 | Oral cavity | OSCC | regulation of cell division | 87/7305 | 177/18723 | 3.75e-03 | 1.55e-02 | 87 |
| GO:00324652 | Oral cavity | OSCC | regulation of cytokinesis | 49/7305 | 92/18723 | 3.81e-03 | 1.57e-02 | 49 |
| GO:00516462 | Oral cavity | OSCC | mitochondrion localization | 28/7305 | 50/18723 | 1.10e-02 | 3.72e-02 | 28 |
| GO:00002661 | Oral cavity | OSCC | mitochondrial fission | 24/7305 | 42/18723 | 1.30e-02 | 4.34e-02 | 24 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MYO19 | SNV | Missense_Mutation | rs532830674 | c.2585G>A | p.Arg862His | p.R862H | Q96H55 | protein_coding | tolerated(0.17) | benign(0.012) | TCGA-A8-A096-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MYO19 | SNV | Missense_Mutation | rs765344804 | c.2794N>T | p.Arg932Trp | p.R932W | Q96H55 | protein_coding | deleterious(0.03) | benign(0.332) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
| MYO19 | insertion | Frame_Shift_Ins | novel | c.2809_2810insTGGT | p.Cys937LeufsTer4 | p.C937Lfs*4 | Q96H55 | protein_coding | TCGA-B6-A0RG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| MYO19 | insertion | Frame_Shift_Ins | novel | c.2807_2808insTTCCGCATTAAATGCAGTAACAGATACCAGTT | p.Cys937SerfsTer33 | p.C937Sfs*33 | Q96H55 | protein_coding | TCGA-B6-A0RG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| MYO19 | SNV | Missense_Mutation | novel | c.2006N>G | p.Tyr669Cys | p.Y669C | Q96H55 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MYO19 | SNV | Missense_Mutation | novel | c.1691N>G | p.Asp564Gly | p.D564G | Q96H55 | protein_coding | tolerated(0.25) | possibly_damaging(0.87) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MYO19 | SNV | Missense_Mutation | novel | c.1588N>A | p.Val530Met | p.V530M | Q96H55 | protein_coding | tolerated(0.14) | benign(0.022) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MYO19 | SNV | Missense_Mutation | rs369381777 | c.584N>A | p.Arg195His | p.R195H | Q96H55 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MYO19 | SNV | Missense_Mutation | rs766865716 | c.670N>G | p.Arg224Gly | p.R224G | Q96H55 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| MYO19 | SNV | Missense_Mutation | rs776257543 | c.2270G>A | p.Arg757His | p.R757H | Q96H55 | protein_coding | deleterious(0) | probably_damaging(0.915) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |